Published in Lancet on March 24, 1984
Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood (2005) 1.39
Prospects for cure in leukaemia. J Clin Pathol (1987) 1.07
T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A (1998) 0.92
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica (2010) 0.87
Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia (2011) 0.83
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia (2015) 0.82
Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am (2011) 0.80
The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean J Pediatr (2011) 0.77
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica (2014) 0.76
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib. Biologics (2016) 0.75
Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev Bras Hematol Hemoter (2015) 0.75
An Innovative Strategy for the Fabrication of Functional Cell Sheets Using an Electroactive Conducting Polymer. Theranostics (2015) 0.75
An overview of bone marrow transplantation for chronic myeloid leukemia. CMAJ (1990) 0.75
Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplant (2014) 0.75
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Hospital characteristics and mortality rates. N Engl J Med (1989) 4.97
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA (1988) 4.46
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
Racial and community factors influencing coronary artery bypass graft surgery rates for all 1986 Medicare patients. JAMA (1992) 4.36
A simple, easy, and inexpensive method for monitoring ETCO2 through nasal cannulae. Anesthesiology (1987) 4.19
Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med (1994) 3.26
Regional variation in the incidence of hip fracture. US white women aged 65 years and older. JAMA (1990) 3.18
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) (1999) 2.85
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Race and sex differences in mortality following fracture of the hip. Am J Public Health (1992) 2.63
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care (2000) 2.36
Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet (1968) 2.29
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis (1999) 2.28
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care (1999) 2.21
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood (1993) 2.12
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant (2008) 2.10
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
Heredopathia atactica polyneuritiformis: Refsum's disease. Acta Neurol Scand (1985) 2.03
Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health (1990) 2.00
Interacting cell populations affecting granulopoietic colony formation by normal and leukemic human marrow cells. Blood (1973) 1.99
Evaluation of the HCFA model for the analysis of mortality following hospitalization. Health Serv Res (1992) 1.99
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood (1997) 1.96
Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood. Blood (1978) 1.96
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 1.94
The relation of body fat distribution, as assessed by six girth measurements, to diabetes mellitus in women. Am J Public Health (1989) 1.94
The association of girth measurements with disease in 32,856 women. Am J Epidemiol (1984) 1.93
Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts. Blood (1979) 1.88
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia (1994) 1.88
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia (1994) 1.88
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood (1998) 1.87
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia (2003) 1.84
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood (2000) 1.84
Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health (1996) 1.83
Carboxyhemoglobin levels in American blood donors. JAMA (1974) 1.82
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia (1995) 1.81
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
The association between hospital type and mortality and length of stay: a study of 16.9 million hospitalized Medicare beneficiaries. Med Care (2000) 1.78
The association of obesity with joint pain and osteoarthritis in the HANES data. J Chronic Dis (1986) 1.78
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Lineage infidelity in acute leukemia. Blood (1983) 1.74
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73
Association between juvenile onset obesity and severe adult obesity in 73, 532 women. Am J Public Health (1976) 1.73
Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA (1993) 1.70
Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med (1987) 1.68
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia (2010) 1.67
Prolymphocytic leukaemia. Br J Haematol (1974) 1.66
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol (2005) 1.65
Relationship of gallbladder disease to parity, obesity, and age. Health Serv Rep (1973) 1.64
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant (2006) 1.63
Clinical trials as a religion. Biomedicine (1978) 1.63
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood (1987) 1.61
Alcohol-related hospitalizations of elderly people. Prevalence and geographic variation in the United States. JAMA (1993) 1.61
Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR) Br J Haematol (1994) 1.60
Bone-marrow transplantation for leukaemia. Lancet (1995) 1.60
Patterns of endoscopic follow-up after surgery for nonmetastatic colorectal cancer. Gastrointest Endosc (2000) 1.59
Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (1987) 1.59
Association between socioeconomic status and obesity in 59,566 women. Prev Med (1974) 1.58
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (1999) 1.58
Increase in circulating stem cells following chemotherapy in man. Blood (1976) 1.58
The association of obesity with infertility and related menstural abnormalities in women. Int J Obes (1979) 1.57
Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol (2002) 1.56
Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol (1978) 1.55
The utility of Medicare claims data for measuring cancer stage. Med Care (1999) 1.54
Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA (1977) 1.54
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53
Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys (1995) 1.53